Kolexia
Yakoub-Agha Ibrahim Biologie médicale
Yakoub-Agha Ibrahim
Biologie médicale
Centre Hospitalier de Lille
Lille, France
996 Activités
2.6 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Maladie du greffon contre l'hôte Leucémie aigüe myéloïde Leucémie myéloïde Lymphomes Syndromes myélodysplasiques Myélome multiple Leucémie-lymphome lymphoblastique à précurseurs B et T Tumeurs hématologiques

Collaborateurs

Voir plus
Mohty Mohamad
Mohty Mohamad
Hôpital Saint-Antoine, Paris, France
Blaise Didier
Blaise Didier
Centre Paoli-Calmettes, Marseille, France
Socie Gerard
Socie Gerard
Hôpital Saint-Louis, Paris, France
Chevallier Patrice
Chevallier Patrice
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Gilead
14 collaboration(s)
Dernière en 2023
Novartis
7 collaboration(s)
Dernière en 2022
A+A
6 collaboration(s)
Dernière en 2022
Biotest
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases: A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis
Essai Clinique (BMS)   06 mars 2024
A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
Leukemia & lymphoma   05 mars 2024
ZUMA-5: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Essai Clinique (Gilead)   23 février 2024
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT.
American journal of hematology   22 février 2024
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
Bone marrow transplantation   21 février 2024
Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Blood cancer journal   19 février 2024
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee.
EClinicalMedicine   10 février 2024
Allogeneic Hematopoietic Cell Transplantation for VEXAS Syndrome: Results of a Multicenter Study of the EBMT.
Blood advances   08 février 2024
HLA Mismatching and Transplant Outcome in the Ptcy Era: A Comprehensive Study By the EBMT Cellular Therapy and Immunobiology Working Party
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
DALY 2-EU: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
Essai Clinique (Miltenyi Biomedicine GmbH)   31 janvier 2024